Searched for
AMBRISENTAN
Stock pick of the week: What has made Cipla a favourite of analystsDue to the recent price correction, the risk-reward ratio of Cipla has turned favourable. Despite the tough environment, the company is tak...- Sun Pharma's Q1 nos: One-off boost likely from US suppliesCentrum Broking expects Sun Pharma's India sales to grow at 7 per cent for the quarter.
- Cipla gets USFDA nod for pulmonary arterial hypertension drugCipla said the US sales of Letairis tablets USP stood at USD 943 million in 2018.
- Load More